PL370430A1 - Sposób podawania peptydu tymozyny alfa 1 - Google Patents
Sposób podawania peptydu tymozyny alfa 1Info
- Publication number
- PL370430A1 PL370430A1 PL02370430A PL37043002A PL370430A1 PL 370430 A1 PL370430 A1 PL 370430A1 PL 02370430 A PL02370430 A PL 02370430A PL 37043002 A PL37043002 A PL 37043002A PL 370430 A1 PL370430 A1 PL 370430A1
- Authority
- PL
- Poland
- Prior art keywords
- peptide
- thymosin alpha
- administering
- patient
- immune
- Prior art date
Links
- 108010078233 Thymalfasin Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 102400000800 Thymosin alpha-1 Human genes 0.000 abstract 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 2
- 229960004231 thymalfasin Drugs 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33087401P | 2001-11-01 | 2001-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL370430A1 true PL370430A1 (pl) | 2005-05-30 |
| PL208388B1 PL208388B1 (pl) | 2011-04-29 |
Family
ID=23291672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL370430A PL208388B1 (pl) | 2001-11-01 | 2002-11-01 | Zastosowanie peptydu tymozyny α 1 (TA1) |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050049191A1 (pl) |
| EP (1) | EP1450850B1 (pl) |
| JP (1) | JP2005511563A (pl) |
| KR (1) | KR20050042229A (pl) |
| CN (1) | CN1582163A (pl) |
| AT (1) | ATE481980T1 (pl) |
| AU (1) | AU2002363248B2 (pl) |
| BR (1) | BR0213823A (pl) |
| CA (1) | CA2464307A1 (pl) |
| DE (1) | DE60237784D1 (pl) |
| EA (1) | EA008536B1 (pl) |
| ES (1) | ES2353379T3 (pl) |
| IL (2) | IL161665A0 (pl) |
| MX (1) | MXPA04004187A (pl) |
| NO (1) | NO327101B1 (pl) |
| NZ (1) | NZ532763A (pl) |
| PL (1) | PL208388B1 (pl) |
| UA (1) | UA80957C2 (pl) |
| WO (1) | WO2003037366A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7897567B2 (en) * | 2002-11-25 | 2011-03-01 | Sciclone Pharmaceuticals, Inc. | Methods of protecting against radiation damage using alpha thymosin |
| DK1613340T3 (da) * | 2003-03-28 | 2010-08-30 | Sciclone Pharmaceuticals Inc | Behandling af aspergillus-infektioner med thymosin alfa 1 |
| US8017129B2 (en) * | 2006-06-15 | 2011-09-13 | SciClone Pharmaceuticals International Ltd | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
| AU2008338594A1 (en) * | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA) |
| WO2010129947A2 (en) | 2009-05-08 | 2010-11-11 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| HK1207008A1 (en) * | 2012-03-08 | 2016-01-22 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for treatment of purulent rhinosinusitis |
| US20130296223A1 (en) | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| JP6821560B2 (ja) * | 2014-10-21 | 2021-01-27 | サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． | 免疫刺激剤による癌治療 |
| AU2016217473B2 (en) * | 2015-02-09 | 2021-07-29 | Sciclone Pharmaceuticals International (Sg) Pte. Ltd. | Thymosin alpha 1 for use in treatment of cystic fibrosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| TW224053B (pl) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| US5468729A (en) * | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
| US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5849596A (en) * | 1996-07-08 | 1998-12-15 | Food Industry Research And Development Institute | Process for determining the smoke content of edible oil |
| AU7788701A (en) * | 2000-07-14 | 2002-01-30 | Transform Pharmaceuticals Inc | System and method for optimizing tissue barrier transfer of compounds |
| EP1343528A2 (en) * | 2000-11-02 | 2003-09-17 | Research Foundation of City University of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
-
2002
- 2002-01-11 UA UA20040504064A patent/UA80957C2/uk unknown
- 2002-11-01 WO PCT/US2002/035093 patent/WO2003037366A1/en not_active Ceased
- 2002-11-01 ES ES02802520T patent/ES2353379T3/es not_active Expired - Lifetime
- 2002-11-01 AU AU2002363248A patent/AU2002363248B2/en not_active Ceased
- 2002-11-01 NZ NZ532763A patent/NZ532763A/en not_active IP Right Cessation
- 2002-11-01 JP JP2003539708A patent/JP2005511563A/ja active Pending
- 2002-11-01 US US10/493,848 patent/US20050049191A1/en not_active Abandoned
- 2002-11-01 AT AT02802520T patent/ATE481980T1/de not_active IP Right Cessation
- 2002-11-01 CN CNA02821871XA patent/CN1582163A/zh active Pending
- 2002-11-01 DE DE60237784T patent/DE60237784D1/de not_active Expired - Lifetime
- 2002-11-01 BR BR0213823-9A patent/BR0213823A/pt not_active IP Right Cessation
- 2002-11-01 EA EA200400591A patent/EA008536B1/ru not_active IP Right Cessation
- 2002-11-01 EP EP02802520A patent/EP1450850B1/en not_active Expired - Lifetime
- 2002-11-01 IL IL16166502A patent/IL161665A0/xx active IP Right Grant
- 2002-11-01 KR KR1020047006674A patent/KR20050042229A/ko not_active Ceased
- 2002-11-01 PL PL370430A patent/PL208388B1/pl not_active IP Right Cessation
- 2002-11-01 CA CA002464307A patent/CA2464307A1/en not_active Abandoned
- 2002-11-01 MX MXPA04004187A patent/MXPA04004187A/es active IP Right Grant
-
2004
- 2004-04-29 IL IL161665A patent/IL161665A/en not_active IP Right Cessation
- 2004-05-21 NO NO20042100A patent/NO327101B1/no not_active IP Right Cessation
-
2010
- 2010-05-07 US US12/775,986 patent/US20100221274A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1450850B1 (en) | 2010-09-22 |
| AU2002363248B2 (en) | 2007-11-22 |
| UA80957C2 (en) | 2007-11-26 |
| DE60237784D1 (de) | 2010-11-04 |
| EP1450850A1 (en) | 2004-09-01 |
| IL161665A0 (en) | 2004-09-27 |
| EA200400591A1 (ru) | 2004-10-28 |
| ATE481980T1 (de) | 2010-10-15 |
| PL208388B1 (pl) | 2011-04-29 |
| CA2464307A1 (en) | 2003-05-08 |
| ES2353379T3 (es) | 2011-03-01 |
| EA008536B1 (ru) | 2007-06-29 |
| CN1582163A (zh) | 2005-02-16 |
| BR0213823A (pt) | 2004-08-31 |
| MXPA04004187A (es) | 2004-07-08 |
| NO20042100D0 (no) | 2004-05-21 |
| EP1450850A4 (en) | 2005-11-30 |
| WO2003037366A1 (en) | 2003-05-08 |
| IL161665A (en) | 2011-03-31 |
| US20100221274A1 (en) | 2010-09-02 |
| NO20042100L (no) | 2004-05-21 |
| KR20050042229A (ko) | 2005-05-06 |
| US20050049191A1 (en) | 2005-03-03 |
| NZ532763A (en) | 2008-01-31 |
| NO327101B1 (no) | 2009-04-20 |
| JP2005511563A (ja) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2000277238A1 (en) | Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy | |
| WO2001060381B1 (en) | Nucleoside analogs with carboxamidine-modified bicyclic base | |
| CA2129541A1 (en) | Method of Promoting Nitrogen Retention in Humans | |
| DK0490991T3 (da) | Doseringsform til oral administration af hypoglykæmisk glipizid | |
| MXPA05006572A (es) | Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad. | |
| WO1987004076A1 (en) | Low dosage of interferon to enhance vaccine efficiency | |
| IL208184A0 (en) | Glp-1, and methods for treating diabetes | |
| DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
| MY103746A (en) | Improvements in or relating to somatostatins | |
| IL161665A0 (en) | Method of administering a thymosin alpha 1 peptide | |
| EA200400548A1 (ru) | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) | |
| IL161670A0 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| JP2002530353A5 (pl) | ||
| DK1173476T3 (da) | Funktionelle sojabönneproteiner | |
| AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
| MY106603A (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| TW200517119A (en) | Method of treatment using interferon-tau | |
| DE69706657D1 (de) | Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen | |
| DK0651649T3 (da) | Fremgangsmåde til administrering af opløsninger af granulocytkolonistimulerende faktor | |
| WO2003072019A3 (en) | Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog | |
| JPS6447715A (en) | Improver for ovulation inductive pregnant genital physiological dysfunction | |
| MD197G2 (ro) | Preparat şi procedeu de tratare a hipogalactiei | |
| MD1780F1 (en) | Method of treatment of patients with hepatic cirrhosis | |
| MD1469G2 (ro) | Metodă de tratament al şocului combustional | |
| AU8716001A (en) | Treatment of hepatitis c with thymosin and pegylated interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification | ||
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20121101 |